AUTHORS
Hedieh Jafari, MS, Liudmyla Tsyba, PhD2, Christoph Weigel, PhD3, Shelby Sloan, PhD4, Aleksiy Palamarchuk, PhD5, Danny Kim6, Ethan Baiochhi7, Shamama Nishat, PhD8, Brian Barta9, Rosario Distefano10, Ian Hout11, Sydney Leon12, Yazeed Sawalha, MD13, David Bond, MD, BS14, Wing Keung Chan, PhD15, Lalit Sehgal, PhD16, Giorgio Inghirami, MD17, Robert A Baiocchi, MD, PhD18, Walter Hanel, MD, PhD19, Lapo Alinari, MD, PhD20
AFFILIATIONS
1 Ohio State University, Columbus, United States
2 Ohio State University, Columbus, United States
3 Ohio State University, Columbus, United States
4 Ohio State University, Columbus, United States
5 Ohio State University, Columbus, United States
6 Ohio State University, Columbus, United States
7 Ohio State University, Columbus, United States
8 Ohio State University, Columbus, United States
9 Ohio State University, Columbus, United States
10 Ohio State University, Columbus, United States
11 Ohio State University, Columbus, United States
12 Ohio State University, Columbus, United States
13 Ohio State University, Columbus, United States
14 Ohio State University, Columbus, United States
15 Ohio State University, Columbus, United States
16 Ohio State University, Columbus, United States
17 Weill Cornell Medicine, New York, United States
18 Ohio State University, Columbus, United States
19 Ohio State University, Columbus, United States
20 Ohio State University, Columbus, United States
ABSTRACT
Introduction: Patients with c-MYC-overexpressing large B-cell lymphomas (LBCLs), including double-expressor diffuse LBCL (DE DLBCL) and high-grade B-cell lymphoma (HGBCL) respond poorly to chemotherapy and have significantly worse clinical outcomes and overall survival than patients with non-c-MYC- overexpressing LBCL. Directly targeting c-MYC remains clinically challenging, highlighting the need to better understand the biology of this disease and identify alternative therapeutic approaches. Transducin Beta-Like 1 (TBL1) proteins belong to a highly conserved family of WD40 repeat-containing proteins that includes TBL1X, TBL1XR1, and TBL1Y. TBL1X and TBL1XR1 (TBL1X/R1) primarily function as adaptor proteins and are best known for their structural roles within transcriptional co-repressor complexes, including NCOR/SMRT. We previously demonstrated that TBL1X/R1 also have post-transcriptional functions in LBCL, including the stabilization of critical oncoproteins such as c-MYC. However, the mechanisms through which TBL1X/R1 regulate c-MYC protein stability remain poorly characterized. In this study, we mechanistically define TBL1X/R1 as critical regulators of c-MYC stability and identify Ubiquitin-Specific Peptidase 1 (USP1), a deubiquitinase implicated in c-MYC regulation, as the mediator of this process.
Methods: The expression of TBL1X, TBL1XR1, c-MYC, and USP1 was determined by immunoblotting in c-MYC-overexpressing LBCL cell lines (n=8, 5 DE DLBCL and 3 HGBCL) and primary patient samples (n=3). Pharmacologic approaches using tegavivint, a first-in-class small molecule targeting TBL1X/R1 (Iterion), and the USP1 inhibitor ML-323 (10 μM for 24 hours), as well as genetic knockout (CRISPR-Cas9) and knockdown (shRNA) of TBL1X, TBL1XR1, and USP1, were used for mechanistic studies. Ubiquitination assays, proteasomal inhibition with MG132 (10 μM for 4 hours), and cycloheximide chase experiments (10 μg/mL) were used to characterize c-MYC and USP1 degradation following pharmacologic targeting or genetic depletion of TBL1X/R1. Co-immunoprecipitation (Co-IP) and in situ proximity ligation assay (PLA) experiments were performed to assess interactions among TBL1X/R1, c-MYC, and USP1 in the presence or absence of tegavivint in c-MYC-overexpressing LBCL cell lines and 293T cells engineered to overexpress FLAG-TBL1X.
Results: Immunoblot analyses demonstrated abundant expression of TBL1X/R1 and USP1 in c-MYC- overexpressing LBCL cell lines (n=8) and primary LBCL patient samples (n=3) compared to normal B cells. Time-course analyses showed that treatment of c-MYC- overexpressing LBCL cell lines (n=4) with tegavivint at the 24-hour IC50, as well as genetic depletion of TBL1X/R1 (n=2), resulted in time-dependent depletion of USP1 and c-MYC protein levels as early as 6 hours, without affecting their transcript levels. Treatment with MG132 rescued the depletion of both proteins, whereas co-treatment with cycloheximide enhanced protein loss indicating enhanced protein degradation rather than transcriptional regulation. These results were further supported by ubiquitination assays demonstrating increased c-MYC ubiquitination following pharmacologic and genetic targeting of TBL1X/R1. Similar results were observed following pharmacologic inhibition of USP1 with ML-323 or shRNA-mediated USP1 knockdown. Mechanistically, Co-IP experiments demonstrated interactions among TBL1X/R1, c-MYC, and USP1. PLA experiments in c-MYC- overexpressing LBCL cell lines (n=2) and 293T cells engineered to overexpress FLAG-TBL1X confirmed the interaction between TBL1X/R1 and USP1, which was disrupted by tegavivint treatment, indicating that TBL1X/R1 interact with USP1 and protect it from proteasomal degradation.
Conclusions: In summary, our study characterizes TBL1X/R1 as critical post-transcriptional regulators of c-MYC stability and identifies USP1 as a key mediator of this effect. Specifically, TBL1X/R1 function as scaffold proteins that recruit USP1 to c-MYC, promoting c-MYC deubiquitination and enhancing its protein stability. These findings identify the TBL1X/R1-USP1 axis as a key regulator of c-MYC stability in c-MYC- overexpressing LBCL and provide a mechanistic rationale for targeting this pathway as a potential therapeutic strategy.
DISCLOSURES
Hedieh Jafari, MS: No relevant conflicts of interest to declare.